

16 June 2026

Eve Initiates Pilot Clinical Study for Libbo ED Film

- Pilot pharmacokinetic study initiated for Libbo, Eve's vardenafil oral soluble film (OSF) for the treatment of erectile dysfunction (ED).
- Study protocol finalised and confirmed.
- Study designed to compare Libbo Vardenafil 10 mg Oral Soluble Film against an Australian-registered reference vardenafil tablet.
- Fasted-state study to be conducted in healthy male subjects.
- Results are intended to inform the design of a subsequent pivotal bioequivalence study and support the regulatory development pathway for Libbo.
- Protocol includes tolerability assessments specific to the oral soluble film formulation.

EVE Health Group Limited (ASX: EVE, EVE or the Company) is pleased to announce that it has initiated its pilot clinical study for Libbo, the Company's vardenafil oral soluble film for the treatment of erectile dysfunction.

The study protocol has now been finalised, enabling commencement of the pilot pharmacokinetic study. The study is designed to compare the pharmacokinetic profile of Libbo Vardenafil 10 mg Oral Soluble Film against an Australian-registered reference vardenafil tablet under fasted conditions in healthy male subjects.

The pilot study represents the first clinical step in the Company's bioequivalence development program for Libbo. Pilot studies are commonly undertaken to confirm study design assumptions and optimise the conduct of a subsequent pivotal bioequivalence study, which is expected to form a key component of the regulatory registration pathway.

The protocol includes patient-reported tolerability assessments designed to evaluate user experience associated with the oral soluble film delivery format.

Libbo's oral soluble film is a rapidly dissolving formulation designed to provide a discreet and convenient alternative to conventional erectile dysfunction tablets. The format may offer advantages in convenience and user experience compared with traditional tablet presentations.

Ben Rohr, Chief Executive Officer of Eve Health Group, commented:

"The initiation of this pilot study marks an important milestone in the development of Libbo. The study is designed to provide valuable information to support the design of our planned pivotal bioequivalence program and represents an important step toward the planned pivotal

bioequivalence study and the commercialisation of a differentiated erectile dysfunction treatment. We look forward to updating shareholders as the study progresses."

Next Steps

Subject recruitment and study activities are expected to proceed over the coming weeks, with pilot study results anticipated during Q3 CY2026. The pilot is expected to generate important pharmacokinetic and tolerability data to support the design and execution of a subsequent pivotal bioequivalence program for Libbo.

Subject to satisfactory outcomes, Eve intends to progress Libbo into a pivotal bioequivalence study designed to support future regulatory registration and commercialisation of the product.

The Company will keep shareholders informed of key milestones as the clinical program advances, including the availability of pilot results and the commencement of the pivotal bioequivalence study.

Authorised for release by the Board of Directors.

Company enquiries

+61 8 6465 5500

info@evehealthgroup.com.au

About EVE Health Group

EVE Health Group (ASX: EVE) is an Australian life sciences company focused on developing and commercialising innovative pharmaceutical solutions in high-growth therapeutic areas. The Company's lead assets include Dyspro®, a fast-acting cannabinoid-based pastille targeting dysmenorrhoea and endometriosis, and Libbo®, an oral dissolving film for erectile dysfunction designed to deliver rapid onset and improved patient convenience. Both products leverage EVE's proprietary formulation and delivery technologies to enhance bioavailability and clinical outcomes, representing near-term commercial opportunities in large, underserved global markets.

EVE is building a vertically integrated health platform that combines proprietary pharmaceutical products with digital education, patient engagement and prescribing pathways. Through its dedicated information platforms, ReclaimMyCycle.com (women's health) and StiffIssue.com (men's health), the Company provides condition-focused education, reduces stigma and supports earlier engagement with appropriate care. These platforms integrate with telehealth and pharmacy fulfilment networks to enable responsible, scalable access to treatment within a regulated healthcare framework.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.